ICDs For Heart Failure: Technical Improvements Will Determine Uptake
This article was originally published in The Gray Sheet
Executive Summary
FDA's decision to approve implantable defibrillators for congestive heart failure is likely to rest on reconciling its desire for mortality data, which will not be available for about two years, with quality-of-life data showing a benefit in some patients.